The analyst confirms his Buy recommendation and price target of E150 after the Investor Day. This target represents a potential upside of 44% compared with the current share price.

' Following Ipsen's CMD, all eyes are on the implementation of forecasts' says UBS.

On the occasion of its investor day (CMD), Ipsen indicated that it was targeting average total sales growth of at least 7% per year for the period 2023-27 at constant exchange rates, and an operating margin from activities of at least 32% of total sales in 2027.

' The mood at Ipsen is generally positive. CMD has a diversified portfolio in the fields of oncology, rare diseases and aesthetic health', stresses the analyst firm.

The pharmaceutical company claims 'several ongoing and potential launches in the short term, including Onivyde, Bylvay, elafibranor and Sohonos, as well as numerous advances in the R&D portfolio in the medium term'.

Copyright (c) 2023 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.